Gilead Sciences, Inc (GILD)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+34% over the past year+3
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityUnprofitable (net margin -12%)-7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product (positive Phase 3 IDEAL data for Livdelzi in PBC), with earnings and dividend news as secondary supports. Continuation likelihood over the next few weeks is moderate (~50-60%), since clinical data can sustain sentiment but near-term drift often depends on broader pharma/macro flows. Informational only — not financial advice.
- Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)Yahoo · 2026-11-05
- Did Earnings Beat Just Shift Gilead Sciences' (GILD) Investment Narrative?Yahoo · 2026-11-05
- Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)SeekingAlpha · 2026-11-05
- Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.Yahoo · 2026-11-05
- What Vir Biotechnology (VIR) Said on Its Q3 Earnings CallYahoo · 2026-11-05
Any AI summary is an interpretation of public news, not advice or a price target.